RTI Health Solutions
15
0
1
13
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
6.7%
1 terminated/withdrawn out of 15 trials
92.9%
+6.4% vs industry average
7%
1 trials in Phase 3/4
8%
1 of 13 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
Study of Pregnancy Outcomes in Women Exposed to Rimegepant During Pregnancy
Role: collaborator
EU Secondary Data Post-Authorisation Safety Study of AZD1222
Role: collaborator
A Safety Study of GAMMAGARD LIQUID (GGL) in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Role: collaborator
Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints
Role: collaborator
Patient and Physician Knowledge of Key Safety Messages
Role: collaborator
Incidence of Second Primary Malignancies in Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the US
Role: collaborator
A Drug Utilisation Post-authorisation Study of New Users of Aclidinium Bromide (Monotherapy or in Combination)
Role: collaborator
Evaluation of Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept
Role: collaborator
Risk Minimisation Study for Diane-35 and Its Generics
Role: collaborator
OSCA - Olaparib Standard of CAre Study
Role: collaborator
Risk of Acute Liver Injury in Users of Antimicrobials
Role: collaborator
NSCLC Burden of Illness Study
Role: collaborator
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Role: collaborator
Asimadoline for the Treatment of Post-Operative Ileus
Role: collaborator
Asimadoline for the Treatment of Subjects With Irritable Bowel Syndrome
Role: collaborator
All 15 trials loaded